VYGR Stock Analysis: Buy, Sell, or Hold?
VYGR - Voyager Therapeutics, Inc. Common Stock
$3.60
0.01 (0.28%)
▲
5d:
-8.4%
30d:
-7.22%
90d:
-12.83%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When VYGR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VYGR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: VYGR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: VYGR is currently trading at $3.60, which is considered oversold relative to its 30-day fair value range of $3.63 to $4.04.
Technical Outlook: Technically, VYGR is showing sideways momentum. Immediate support is located at $3.36, while resistance sits at $4.04.
Market Sentiment: VYGR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (28th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.89 (+313.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VYGR is showing sideways momentum. Immediate support is located at $3.36, while resistance sits at $4.04.
Market Sentiment: VYGR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (28th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.89 (+313.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.63 -
$4.04
Company Quality Score
53/100
(HOLD)
Options IV Signal
28th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 28th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 313.6% below Wall St target ($14.89)
- CAUTION: Recommendation downgraded due to -8.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$3.63 -
$4.04
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.56
(15.7%)
Support & Resistance Levels
Support Level
$3.36
Resistance Level
$4.04
Current Trend
Sideways
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.28
Wall Street Target
$14.89
(+313.6%)
Revenue Growth (YoY)
-59.9%
Share & Embed Analysis
Last updated: June 03, 2026 5:36 PM ET
Data refreshes hourly during market hours. Next update: 6:36 PM
Data refreshes hourly during market hours. Next update: 6:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYGR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Alfred Sandrock
SELL
11511 shares
2026-04-02
Alfred Sandrock
SELL
14197 shares
2026-02-24
Nathan D Jorgensen
SELL
4668 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 52 HOLD |
